Suppr超能文献

无创通气在急性重症哮喘中是否安全?

Is non-invasive ventilation safe in acute severe asthma?

作者信息

Pallin Michael, Hew Mark, Naughton Matthew T

机构信息

Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Monash University, Melbourne, Victoria, Australia.

出版信息

Respirology. 2015 Feb;20(2):251-7. doi: 10.1111/resp.12428. Epub 2014 Nov 6.

Abstract

BACKGROUND AND OBJECTIVE

The effect of non-invasive ventilation (NIV) in acute severe asthma is unclear and there are concerns regarding its safety.

METHODS

We undertook a 5-year case-control review of mortality and morbidity associated with NIV use in acute severe asthma and compared this with asthma requiring invasive mechanical ventilation (IMV) and a control group with less severe asthma without ventilatory support.

RESULTS

Eight hundred seventy-three patients had acute severe asthma of whom 30 were treated with NIV, 17 with IMV and 90 served as controls. The mean duration of NIV was 9.5 ± 7.3 h with inspiratory positive airway pressure and expiratory positive airway pressure of 11.9 ± 1.4 and 5.8 ± 1.2 cmH2 O respectively. Mortality was zero in the NIV and control groups, compared with 41% in the IMV group. None of the NIV or control groups required escalation to invasive ventilation. There were no instances of haemodynamic compromise in the NIV or control groups. Length of hospital stay was 121 ± 96 h in the NIV group and similar to the severe IMV group (136 ± 99 h, P > 0.05) and significantly longer than the control group (42 ± 40 h, P < 0.05).

CONCLUSIONS

NIV can be safely used in acute severe asthma although further work is needed to delineate the precise patient selection process.

摘要

背景与目的

无创通气(NIV)在急性重症哮喘中的作用尚不清楚,且其安全性也备受关注。

方法

我们对急性重症哮喘患者使用NIV的死亡率和发病率进行了为期5年的病例对照研究,并将其与需要有创机械通气(IMV)的哮喘患者以及无需通气支持的轻症哮喘对照组进行比较。

结果

873例患者患有急性重症哮喘,其中30例接受了NIV治疗,17例接受了IMV治疗,90例作为对照。NIV的平均持续时间为9.5±7.3小时,吸气气道正压和呼气气道正压分别为11.9±1.4和5.8±1.2 cmH2O。NIV组和对照组的死亡率为零,而IMV组为41%。NIV组和对照组均无需升级为有创通气。NIV组和对照组均未出现血流动力学不稳定的情况。NIV组的住院时间为121±96小时,与重症IMV组相似(136±99小时,P>0.05),且显著长于对照组(42±40小时,P<0.05)。

结论

NIV可安全用于急性重症哮喘,尽管还需要进一步研究以明确精确的患者选择流程。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验